Abstract
Cardiovascular complications are the leading cause of mortality, accounting for 50% of all deaths among patients with end-stage renal disease (ESRD). The majority of these deaths are from cardiac causes. The mechanisms underlying the enhanced susceptibility to myocardial ischaemia and subsequent morbidity in ESRD remain ill-defined. Numerous metabolic derangements accompany myocardial ischaemia and reperfusion and play a pivotal role in the development of concurrent myocardial dysfunction. Carnitine plays a critical role in myocardial energy metabolism, as the transporter of long chain fatty acyl intermediates across the inner mitochondrial membrane for β oxidation and as a central regulator of carbohydrate metabolism. Myocardial carnitine is significantly depleted during ischaemia and more particularly in uraemic patients and those on dialysis therapy. Carnitine treatment has cardiovascular benefits including modulation of myocardial metabolism, reduction in necrotic cell death and infarct size, decrease in the incidence of arrhythmias and preservation of mechanical function. This review details the profile of substrate metabolism in the uraemic heart and the impact of carnitine supplementation on metabolism and function of the reperfused heart and finally the experimental and clinical evidence for carnitine replacement therapy, in particular its impact on the uraemic heart via modulation of function and energetics.
Keywords: Cardiac disease, carnitine, chronic kidney disease, dialysis, cardiovascular complications, uraemia, animal models, arrhythmia, carbohydrate metabolism, clinical studies
Current Drug Targets
Title: Value of Carnitine Therapy in Kidney Dialysis Patients and Effects on Cardiac Function from Human and Animal Studies
Volume: 13 Issue: 2
Author(s): Rebekah Molyneux, A-M Seymour and Sunil Bhandari
Affiliation:
Keywords: Cardiac disease, carnitine, chronic kidney disease, dialysis, cardiovascular complications, uraemia, animal models, arrhythmia, carbohydrate metabolism, clinical studies
Abstract: Cardiovascular complications are the leading cause of mortality, accounting for 50% of all deaths among patients with end-stage renal disease (ESRD). The majority of these deaths are from cardiac causes. The mechanisms underlying the enhanced susceptibility to myocardial ischaemia and subsequent morbidity in ESRD remain ill-defined. Numerous metabolic derangements accompany myocardial ischaemia and reperfusion and play a pivotal role in the development of concurrent myocardial dysfunction. Carnitine plays a critical role in myocardial energy metabolism, as the transporter of long chain fatty acyl intermediates across the inner mitochondrial membrane for β oxidation and as a central regulator of carbohydrate metabolism. Myocardial carnitine is significantly depleted during ischaemia and more particularly in uraemic patients and those on dialysis therapy. Carnitine treatment has cardiovascular benefits including modulation of myocardial metabolism, reduction in necrotic cell death and infarct size, decrease in the incidence of arrhythmias and preservation of mechanical function. This review details the profile of substrate metabolism in the uraemic heart and the impact of carnitine supplementation on metabolism and function of the reperfused heart and finally the experimental and clinical evidence for carnitine replacement therapy, in particular its impact on the uraemic heart via modulation of function and energetics.
Export Options
About this article
Cite this article as:
Molyneux Rebekah, Seymour A-M and Bhandari Sunil, Value of Carnitine Therapy in Kidney Dialysis Patients and Effects on Cardiac Function from Human and Animal Studies, Current Drug Targets 2012; 13 (2) . https://dx.doi.org/10.2174/138945012799201595
DOI https://dx.doi.org/10.2174/138945012799201595 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chest X-ray in Sarcoidosis: The Association of Age, Gender, and Ethnicity with Different Radiological Findings
Current Respiratory Medicine Reviews Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy
Current Gene Therapy New Insights into the Surgical Management of Tetralogy of Fallot: Physiological Fundamentals and Clinical Relevance
Current Pediatric Reviews The Failing Heart in Pediatric Dilated Cardiomyopathy Caused by Excessive Water Drinking: A Case Report and Brief Review
New Emirates Medical Journal Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy Recent Advances and Patents on Coronary Sinus Perfusion Devices for Treatment of Heart Disease
Recent Patents on Biomedical Engineering (Discontinued) Protective Effects of Curcumin against Iron-induced Toxicity
Current Pharmaceutical Biotechnology Diagnostic Imaging of Fetal and Neonatal Abdominal and Soft Tissue Tumors
Current Pediatric Reviews Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Angiotensin-Converting Enzyme Inhibitors: Mechanisms of Action and Implications In Anesthesia Practice
Current Pharmaceutical Design Moxifloxacin-induced Hypoglycemia in a Non-diabetic Patient
Current Drug Safety Clinical Characteristics and Treatment of Cardiomyopathies in Children
Current Cardiology Reviews Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry Pathophysiology of Post-Operative Low Cardiac Output Syndrome
Current Vascular Pharmacology Peripartum Cardiomyopathy: An Intensivist's Perspective
Current Women`s Health Reviews The GH/IGF-1 Axis in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Juvenile Systemic Lupus Erythematosus
Current Pediatric Reviews The GH/IGF-1 Axis and Heart Failure
Current Cardiology Reviews Pulmonary Complications After Congenital Heart Surgery
Current Respiratory Medicine Reviews Perinatal Heart Programming: Long-term Consequences
Current Medicinal Chemistry